Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Until today this year the stock’s price performance recorded an increase of 31.49%. However, over the last six months, the performance has been stronger by -38.89%. The price of NEUP increased 42.72% over the last 30 days. And in the last five days, it has fallen by -12.43%.
Neuphoria Therapeutics Inc’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $16.08 on 02/14/24, and the lowest price during that time was $2.12, recorded on 10/28/24.
52-week price history of NEUP Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Neuphoria Therapeutics Inc’s current trading price is -71.95% away from its 52-week high, while its distance from the 52-week low is 112.34%. The stock’s price range for this period has been between $2.12 and $16.08. The Healthcare sector company’s shares saw a trading volume of about 2.74 million for the day, which was higher than the average daily volume of 0.57 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Neuphoria Therapeutics Inc (NEUP) has experienced a quarterly decline of -7.16% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.23M and boasts a workforce of 24 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.99, with a change in price of -3.08. Similarly, Neuphoria Therapeutics Inc recorded 866,132 in trading volume during the last 100 days, posting a change of -40.01%.
NEUP’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for NEUP stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
NEUP Stock Stochastic Average
As of today, the raw stochastic average of Neuphoria Therapeutics Inc over the past 50 days is 18.94%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 16.96%. Additionally, the Stochastic %K and %D values for the company were 16.75% and 17.58%, respectively, over the past 20 days.
